Artivion Inc
Research Artivion Inc (AORT) on Bullrun: valuation model: 41.9% overvalued, market cap USD 1.09B, P/E 93.2. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAORT
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Valuation signal41.9% overvalued
- Market capUSD 1.09B
- P/E93.2
- Financial periodFY2025
- RevenueUSD 441.33M
- Revenue growth13.6%
- Net incomeUSD 9.77M
- Free cash flowUSD 839.00K
- Gross margin64.4%
Valuation Snapshot
Bullrun's latest valuation model marks Artivion Inc as 41.9% overvalued; latest market cap is USD 1.09B; P/E is 93.2.
About Artivion Inc
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system;
Frequently asked questions
Is Artivion Inc overvalued or undervalued?
Bullrun's valuation model currently marks Artivion Inc as 41.9% overvalued.
What is Artivion Inc's market cap?
Artivion Inc's market capitalization is USD 1.09B.
What is Artivion Inc's P/E ratio?
Artivion Inc's price-to-earnings (P/E) ratio is 93.2.
What does Artivion Inc do?
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures;